Arrowhead Pharmaceuticals reported early human evidence that an RNA interference medicine injected under the skin can cross into the brain and suppress production of tau, a protein whose accumulation tracks Alzheimer disease progression. The company called the result clinical validation of its delivery platform for targets outside the liver, the standing limitation of the RNA field.
The trial enrolled about 64 healthy volunteers across three dose regimens. Participants received 2.1 or 6.4 milligrams per kilogram on days one, eight and 15, or 12.8 milligrams per kilogram on days one and 15. At day 105, tau levels had fallen 40 percent at the lowest dose and 69 percent at the middle dose. In the high dose group the average reduction was 73 percent, with reductions as deep as 85 percent in some participants, a durability that suggests dosing as infrequently as once every three months. Side effects were described as mild, mainly injection site reactions, bruising, respiratory infections and headaches.
The context is a field with approved drugs that address amyloid, the other hallmark Alzheimer protein, but deliver modest benefit and carry safety constraints, while tau directed programs have repeatedly struggled to show a clean effect. A Stifel analyst note quoted in the trade coverage called the data compelling for a subcutaneous drug, while cautioning that the program is very early and tau itself is not yet a proven target whose lowering guarantees clinical benefit.
That caution is the correct frame. This was a safety first study in healthy people, measuring a biomarker, not cognition. The remaining cohorts add people with mild Alzheimer disease receiving up to five injections, and Arrowhead plans studies in frontotemporal dementia and progressive supranuclear palsy, two rarer tau disorders where a treatment effect may be easier to isolate. The commercial question, whether tau suppression slows disease, is years from an answer; the platform question, whether RNA drugs can be delivered to the brain without intrathecal injection, now has its first affirmative human data point.